ArticleOpen veterinary journal2025
Histomorphological evaluation of docetaxel effects on testes and epididymides in Wistar rats.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.World journal of urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy drugs, such as Docetaxel, which are crucial for treating cancer, frequently cause unknowingly damage to healthy tissues. Aim: To investigate the histomorphological effects of docetaxel chemotherapy on certain parameters in testes and epididymides. Method: For this purpose, 24 Wistar Albino rats were divided randomly into one control group and three treatment groups. The treatment groups were administered 2.5, 5, and 10 mg/kg of the drug. The experiment lasted for 28 days. The weights of the testes and epididymides were measured. The testicular and epididymal samples were subjected to histological analysis and were examined under a light microscope. Result: The results revealed that the dose of DX1 (2.5 mg/kg) of docetaxel had no adverse effect on the process of spermatogenesis; however, the highest doses of DX2 and DX3 penetrated the blood-testis barrier and disrupted the structural and functional system of spermatogenesis. The results of the present study indicate that the highest dose of docetaxel leads to adverse effects on testes, epididymides, and their fertility parameters. In addition, the testicular tissues of DX2 and DX3 displayed adverse histomorphological changes. The process of spermatogenesis was interrupted, and a progressive decrease in the height of the germinal epithelium was observed. On this basis, the weight of the testes and epididymides decreased. Conclusion: A dose of 2.5 mg/kg of Docetaxel was the drug of choice for chemotherapy. Further studies are needed to investigate the long-term effects of Docetaxel on male fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.